

Pharmacy BULLETIN BOARD

Retail Issue ■ Monday January 13, 2014.

Odan Labs wishes to remind you that **Adasept® Skin Cleanser** and **Tardan® Shampoo** are ideal therapeutic replacements for the discontinued products **Tersaseptic†** and **Polytar†**.

Product	DIN	Comparative	Sizes	Odan Code	UPC
Adasept® Skin Cleanser	00266507	Tersaseptic†	250 mL	020J	776097020251
			500 mL	020L	776097020503
Tardan® Shampoo	00266493	Polytar†	250 mL	170J	776097170253
			500 mL	170L	776097170505

Adasept® Antibacterial Cleanser and **Tardan®** dandruff shampoo are prescribed by dermatologists and physicians across Canada. Both products are used in hospitals and by patients nationwide.



To order, please contact your preferred wholesaler or contact Odan at 1-800-387-9342 or by e-mail at info@odanlab.com. You can also visit our website at www.odanlab.com.

Adasept® and Tardan® are registered trademarks of Odan Laboratories Ltd.
† Tersaseptic and Polytar are trademarks of Stiefel, a GSK company

■ FROM THE NEWSWIRE ■

MISSISSAUGA, ON: GlaxoSmithKline Inc. and Theravance Inc. announced that ANORO™ ELLIPTA™ was approved in Canada on December 23, 2013, for the long-term once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

LAVAL, QC: BELLUS Health Inc. a drug development company focused on rare diseases, announced an update on the ongoing Phase III study for KIACTA™, a drug candidate for patients with AA amyloidosis. The Phase III Confirmatory Study is designed to confirm the safety and efficacy of KIACTA™, previously demonstrated in a Phase II/III study, in preventing kidney function decline in patients diagnosed with AA amyloidosis. AA amyloidosis is an orphan indication resulting in kidney dysfunction that often rapidly leads to dialysis and death.

BURLINGTON, ON: Canada celebrated the official opening of its expanded Canadian healthcare distribution network - a state-of-the-art 200,000 square foot facility at its Burlington, Ontario, campus. As one of the largest cold-chain coolers in the country, the new addition provides healthcare companies and pharmaceutical manufacturers increased access to a total 600,000 square-feet worth of temperature and humidity-controlled environments - effectively helping keep products in optimal conditions during storage.

DORVAL, QC: Novartis Pharmaceuticals Canada Inc. (Novartis) announced that Health Canada has approved the use of ILARIS (canakinumab) in the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged two years and older. SJIA is a rare and disabling form of childhood arthritis with limited treatment options. The condition is characterized by spiking fever, rash and arthritis that can affect children as young as two years old and can continue into adulthood.